18 results on '"Baldi, T."'
Search Results
2. Sistema per guidare il passo di un soggetto
- Author
-
Prattichizzo, D., Aggravi, M., Rossi, S., Mohammadi, M., Lisini Baldi, T., and Cioncoloni, D.
- Published
- 2016
3. Predictors of in-hospital mortality in elderly patients with acute venous thrombo-embolism: the SWIss Venous ThromboEmbolism Registry (SWIVTER)
- Author
-
Spirk, D., primary, Husmann, M., additional, Hayoz, D., additional, Baldi, T., additional, Frauchiger, B., additional, Engelberger, R., additional, Amann-Vesti, B., additional, Baumgartner, I., additional, and Kucher, N., additional
- Published
- 2011
- Full Text
- View/download PDF
4. Intermittierende Claudicatio, wörtlich gemeint
- Author
-
Reutlinger, C, primary, Koella, C, additional, Korteweg, E, additional, Baldi, T, additional, and Jeanneret, C, additional
- Published
- 2006
- Full Text
- View/download PDF
5. Die oberflächliche Thrombophlebitis: ein Überblick
- Author
-
Jeanneret, C, primary, Baldi, T, additional, and Jenelten, R, additional
- Published
- 2006
- Full Text
- View/download PDF
6. La thrombophlébite superficielle: une vue d'ensemble
- Author
-
Jeanneret, C, primary, Baldi, T, additional, and Jenelten, R, additional
- Published
- 2006
- Full Text
- View/download PDF
7. The tide-influenced Pétervására sandstone, early Miocene, Northern Hungary: sedimentology, palaeogeography and basin development
- Author
-
Sztanó, O., IVAU: Instituut voor Aardwetenschappen Utrecht, Sedimentology, Eisma, Doeke, Baldi, T., de Boer, Poppe, and University Utrecht
- Subjects
sedimentologie / Noord-Hongarije ,Aardwetenschappen ,paleogeografie / Noord-Hongarije - Abstract
The objectives of this thesis are: - to determine the main sedimentary units, the dominant depositional processes, and to reconstruct the depositional environment of the Lower Miocene Petervasara Sandstone (Chapter 3), - to show the pattern of sediment dispersal in connection with the potential effects of small-scale syntectonic processes (Chapter 4), - to document and interpret the tide-inftuenced system (Chapter 5), - to understand its oceanographical background and the reasons for the development of the tidal inftuence (Chapter 7), - to analyze the potential palaeogeographic connections implied by the tide-inftuenced deposits in the basin, with other Early Miocene basins in the Central Paratethys region (Chapter 6), - to pinpoint stratigraphic markers and to establish chronostratigraphic correlations within the formation and also with coeval deposits (Chapter 4 and 8), - to determine the main controlling factors in the development of the depositional environment of the Petervasara Sandstone, and to distinguish signals of tectonics and eustasy (Chapter 8).
- Published
- 1994
8. Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Detailed Description of the Technical Performance, Clinical Utility, and Platform Comparison.
- Author
-
Petrova-Drus K, Syed M, Yu W, Hutt K, Zlotnicki AM, Huang Y, Kamalska-Cyganik M, Maciag L, Wang M, Ma YG, Ho C, Moung C, Yao J, Nafa K, Baik J, Vanderbilt CM, Benhamida JK, Liu Y, Zhu M, Durham B, Ewalt MD, Salazar P, Rijo I, Baldi T, Mato A, Roeker LE, Roshal M, Dogan A, and Arcila ME
- Subjects
- Humans, Immunoglobulin Heavy Chains genetics, Gene Rearrangement, High-Throughput Nucleotide Sequencing methods, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Lymphoma, B-Cell genetics
- Abstract
Somatic hypermutation status of the IGHV gene is essential for treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Unlike the conventional low-throughput method, assessment of somatic hypermutation by next-generation sequencing (NGS) has potential for uniformity and scalability. However, it lacks standardization or guidelines for routine clinical use. We critically assessed the performance of an amplicon-based NGS assay across 458 samples. Using a validation cohort (35 samples), the comparison of two platforms (Ion Torrent versus Illumina) and two primer sets [leader versus framework region 1 (FR1)] in their ability to identify clonotypic IGHV rearrangement(s) revealed 97% concordance. The mutation rates were identical by both platforms when using the same primer set (FR1), whereas a slight overestimation bias (+0.326%) was found when comparing FR1 with leader primers. However, for nearly all patients this did not affect the stratification into mutated or unmutated categories, suggesting that use of FR1 may provide comparable results if leader sequencing is not available and allowing for a simpler NGS laboratory workflow. In routine clinical practice (423 samples), the productive rearrangement was successfully detected by either primer set (leader, 97.7%; FR1, 94.7%), and a combination of both in problematic cases reduced the failure rate to 1.2%. Higher sensitivity of the NGS-based analysis also detected a higher frequency of double IGHV rearrangements (19.1%) compared with traditional approaches., (Copyright © 2023 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
9. A Human Gesture Mapping Method to Control a Multi-Functional Hand for Robot-Assisted Laparoscopic Surgery: The MUSHA Case.
- Author
-
Ficuciello F, Villani A, Lisini Baldi T, and Prattichizzo D
- Abstract
This work presents a novel technique to control multi-functional hand for robot-assisted laparoscopic surgery. We tested the technique using the MUSHA multi-functional hand, a robot-aided minimally invasive surgery tool with more degrees of freedom than the standard commercial end-effector of the da Vinci robot. Extra degrees of freedom require the development of a proper control strategy to guarantee high performance and avoid an increasing complexity of control consoles. However, developing reliable control algorithms while reducing the control side's mechanical complexity is still an open challenge. In the proposed solution, we present a control strategy that projects the human hand motions into the robot actuation space. The human hand motions are tracked by a LeapMotion camera and mapped into the actuation space of the virtualized end-effector. The effectiveness of the proposed method was evaluated in a twofold manner. Firstly, we verified the Lyapunov stability of the algorithm, then an user study with 10 subjects assessed the intuitiveness and usability of the system., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Ficuciello, Villani, Lisini Baldi and Prattichizzo.)
- Published
- 2021
- Full Text
- View/download PDF
10. Emerging of new bioartificial corticospinal motor synergies using a robotic additional thumb.
- Author
-
Rossi S, Salvietti G, Neri F, Romanella SM, Cinti A, Sinigaglia C, Ulivelli M, Lisini Baldi T, Santarnecchi E, and Prattichizzo D
- Subjects
- Adult, Artificial Limbs, Evoked Potentials, Motor, Female, Humans, Magnetic Resonance Imaging, Male, Motor Cortex diagnostic imaging, Motor Neurons physiology, Motor Skills, Thumb innervation, Motor Cortex physiology, Pyramidal Tracts physiology, Robotics instrumentation, Thumb physiology
- Abstract
It is likely that when using an artificially augmented hand with six fingers, the natural five plus a robotic one, corticospinal motor synergies controlling grasping actions might be different. However, no direct neurophysiological evidence for this reasonable assumption is available yet. We used transcranial magnetic stimulation of the primary motor cortex to directly address this issue during motor imagery of objects' grasping actions performed with or without the Soft Sixth Finger (SSF). The SSF is a wearable robotic additional thumb patented for helping patients with hand paresis and inherent loss of thumb opposition abilities. To this aim, we capitalized from the solid notion that neural circuits and mechanisms underlying motor imagery overlap those of physiological voluntary actions. After a few minutes of training, healthy humans wearing the SSF rapidly reshaped the pattern of corticospinal outputs towards forearm and hand muscles governing imagined grasping actions of different objects, suggesting the possibility that the extra finger might rapidly be encoded into the user's body schema, which is integral part of the frontal-parietal grasping network. Such neural signatures might explain how the motor system of human beings is open to very quickly welcoming emerging augmentative bioartificial corticospinal grasping strategies. Such an ability might represent the functional substrate of a final common pathway the brain might count on towards new interactions with the surrounding objects within the peripersonal space. Findings provide a neurophysiological framework for implementing augmentative robotic tools in humans and for the exploitation of the SSF in conceptually new rehabilitation settings., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
11. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS.
- Author
-
Rose Brannon A, Jayakumaran G, Diosdado M, Patel J, Razumova A, Hu Y, Meng F, Haque M, Sadowska J, Murphy BJ, Baldi T, Johnson I, Ptashkin R, Hasan M, Srinivasan P, Rema AB, Rijo I, Agarunov A, Won H, Perera D, Brown DN, Samoila A, Jing X, Gedvilaite E, Yang JL, Stephens DP, Dix JM, DeGroat N, Nafa K, Syed A, Li A, Lebow ES, Bowman AS, Ferguson DC, Liu Y, Mata DA, Sharma R, Yang SR, Bale T, Benhamida JK, Chang JC, Dogan S, Hameed MR, Hechtman JF, Moung C, Ross DS, Vakiani E, Vanderbilt CM, Yao J, Razavi P, Smyth LM, Chandarlapaty S, Iyer G, Abida W, Harding JJ, Krantz B, O'Reilly E, Yu HA, Li BT, Rudin CM, Diaz L, Solit DB, Arcila ME, Ladanyi M, Loomis B, Tsui D, Berger MF, Zehir A, and Benayed R
- Subjects
- DNA Mutational Analysis methods, Gene Frequency genetics, High-Throughput Nucleotide Sequencing, Humans, Mutation genetics, Neoplasms blood, Neoplasms pathology, Biomarkers, Tumor genetics, Circulating Tumor DNA genetics, Genetic Markers genetics, Neoplasms genetics
- Abstract
Circulating cell-free DNA from blood plasma of cancer patients can be used to non-invasively interrogate somatic tumor alterations. Here we develop MSK-ACCESS (Memorial Sloan Kettering - Analysis of Circulating cfDNA to Examine Somatic Status), an NGS assay for detection of very low frequency somatic alterations in 129 genes. Analytical validation demonstrated 92% sensitivity in de-novo mutation calling down to 0.5% allele frequency and 99% for a priori mutation profiling. To evaluate the performance of MSK-ACCESS, we report results from 681 prospective blood samples that underwent clinical analysis to guide patient management. Somatic alterations are detected in 73% of the samples, 56% of which have clinically actionable alterations. The utilization of matched normal sequencing allows retention of somatic alterations while removing over 10,000 germline and clonal hematopoiesis variants. Our experience illustrates the importance of analyzing matched normal samples when interpreting cfDNA results and highlights the importance of cfDNA as a genomic profiling source for cancer patients.
- Published
- 2021
- Full Text
- View/download PDF
12. Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms.
- Author
-
Arcila ME, Yu W, Syed M, Kim H, Maciag L, Yao J, Ho C, Petrova K, Moung C, Salazar P, Rijo I, Baldi T, Zehir A, Landgren O, Park J, Roshal M, Dogan A, and Nafa K
- Subjects
- Electrophoresis, Capillary, Humans, B-Lymphocytes metabolism, High-Throughput Nucleotide Sequencing methods, Immunoglobulin Heavy Chains analysis, Neoplasms, Plasma Cell metabolism
- Abstract
Immunoglobulin heavy chain (IGH) clonality testing by next-generation sequencing (NGS) offers unique advantages over current low-throughput methods in the assessment of B-cell lineage neoplasms. Clinical use remains limited because assays are not standardized and validation/implementation guidelines are not yet developed. Herein, we describe our clinical validation and implementation of NGS IGH clonality testing and summarize our experience based on extensive routine use. NGS-based clonality testing targeting IGH FR1, FR2, FR3, and the conserved leader sequence upstream of FR1 was validated using commercially available kits. Data were analyzed by commercial and in-house-developed bioinformatics pipelines. Performance characteristics were evaluated directly comparing with capillary electrophoresis (CE) assays (BIOMED-2 primers). Assays were monitored after implementation (>1.5 years), concurrently testing by CE methods. A total of 1189 clinical samples were studied (94 validation, 1095 postimplementation). NGS showed superior performance compared with CE assays. For initial assessment, clonality detection rate was >97% for all malignancy types. Concordance with CE was 96%; discordances were related to higher sensitivity/resolution of NGS and improved detection in cases with high somatic hypermutation. Routine NGS clonality assessment is feasible and superior to existing assays, enabling accurate and specific index clone assessment and future tracking of all rearrangements in a patient sample. Successful implementation requires new standardization, validation, and implementation processes, which should be performed as a multicenter and multidisciplinary collaboration., (Copyright © 2019 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
13. Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
- Author
-
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, and Berger MF
- Published
- 2017
- Full Text
- View/download PDF
14. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
- Author
-
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, and Berger MF
- Subjects
- Cohort Studies, Data Mining, Feasibility Studies, Female, Genomics, High-Throughput Nucleotide Sequencing, Humans, Male, Mutation, Neoplasms pathology, Prospective Studies, Sequence Analysis, DNA, Biomarkers, Tumor genetics, DNA, Neoplasm genetics, Neoplasm Metastasis genetics, Neoplasms genetics
- Abstract
Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of genomic alterations in genes and pathways that can be targeted therapeutically. The existence of recurrent targetable alterations across distinct histologically defined tumor types, coupled with an expanding portfolio of molecularly targeted therapies, demands flexible and comprehensive approaches to profile clinically relevant genes across the full spectrum of cancers. We established a large-scale, prospective clinical sequencing initiative using a comprehensive assay, MSK-IMPACT, through which we have compiled tumor and matched normal sequence data from a unique cohort of more than 10,000 patients with advanced cancer and available pathological and clinical annotations. Using these data, we identified clinically relevant somatic mutations, novel noncoding alterations, and mutational signatures that were shared by common and rare tumor types. Patients were enrolled on genomically matched clinical trials at a rate of 11%. To enable discovery of novel biomarkers and deeper investigation into rare alterations and tumor types, all results are publicly accessible.
- Published
- 2017
- Full Text
- View/download PDF
15. The ultrasound compression sign to diagnose temporal giant cell arteritis shows an excellent interobserver agreement.
- Author
-
Aschwanden M, Imfeld S, Staub D, Baldi T, Walker UA, Berger CT, Hess C, and Daikeler T
- Subjects
- Aged, Aged, 80 and over, Cohort Studies, Female, Giant Cell Arteritis diagnosis, Humans, Male, Middle Aged, Observer Variation, Prospective Studies, Reproducibility of Results, Rheumatology, Ultrasonography, Doppler, Duplex, Giant Cell Arteritis diagnostic imaging, Temporal Arteries diagnostic imaging
- Abstract
Objectives: To compare the diagnostic performance between a vascular specialist and a rheumatologist not familiar with vascular ultrasound when applying the compression sign for the diagnosis of temporal arteritis., Methods: Sixty consecutive patients with suspicion of giant cell arteritis were examined by both examiners. Compression of the temporal artery on both sides (stem and both branches) was performed to define whether signs of vasculitis, no vasculitis or an indefinite result were present. Each examiner was blinded to the result of the other., Results: In 59/60 patients, the examiners found an identical result. The interobserver agreement (Krippendorf alpha) was 0.92., Conclusions: The new compression sign for the diagnosis of temporal arteritis is a simple and robust sonographic marker with an excellent interobserver agreement.
- Published
- 2015
16. Assessment of microcirculation by contrast-enhanced ultrasound: a new approach in vascular medicine.
- Author
-
Kaspar M, Partovi S, Aschwanden M, Imfeld S, Baldi T, Uthoff H, and Staub D
- Subjects
- Cardiology, Carotid Stenosis diagnostic imaging, Contrast Media, Humans, Kidney Diseases diagnostic imaging, Muscle, Skeletal diagnostic imaging, Peripheral Arterial Disease diagnostic imaging, Coronary Artery Disease diagnostic imaging, Microcirculation, Plaque, Atherosclerotic diagnostic imaging, Ultrasonography methods
- Abstract
Contrast-enhanced ultrasound (CEUS) has emerged as a valuable imaging modality that complements and enhances standard vascular ultrasound imaging. Ultrasound contrast agents are gas-filled microbubbles that are injected intravenously and serve as intravascular tracers. Based on the properties to enhance and to quantify the macro- and microcirculation down to the capillary perfusion level in different vascular territories and organs, CEUS imaging has the potential to improve the diagnostic performance in the detection and characterisation of various vascular disorders reviewed in this article. In carotid atherosclerotic disease, CEUS imaging provides additional information on plaque vulnerability by illustrating the presence and extent of intraplaque neovascularisation. This new imaging modality may be helpful for further risk stratification of arteriosclerotic lesions and for detecting patients at risk for vascular events, eventually leading to more specific individually tailored therapeutic recommendations. CEUS imaging is also a helpful tool for the diagnosis and for monitoring of inflammatory vascular diseases. It increases the diagnostic performance of ultrasound in detecting inflammatory changes of the vessel wall such as hypervascularisation and hyperaemia. Changes in vessel wall enhancement may also reflect the response to anti-inflammatory therapy. Moreover, CEUS imaging is also a valuable tool for the assessment of the microcirculation and the tissue perfusion in solid organs including native and transplanted kidneys. The technique provides more accurate information on perfusion deficits of the parenchyma in patients with kidney infarction, necrosis or graft dysfunction. CEUS also has great potential in the assessment of the microcirculation of the skeletal muscle, particularly in patients with peripheral artery disease or diabetic microangiopathy. In the future, the use of targeted on site microbubbles could further enhance and expand the diagnostic capabilities of current vascular ultrasound by assessing specific molecular processes that play a role in the pathophysiology of vascular diseases. Furthermore, ultrasound-directed, site-specific drug and gene delivery using microbubble contrast agents could gain great clinical value in the future. The combination of CEUS for diagnosis and therapy will provide unique opportunities for vascular clinicians to image the microcirculation and directly treat vascular diseases.
- Published
- 2015
- Full Text
- View/download PDF
17. Use of biomarkers or echocardiography in pulmonary embolism: the Swiss Venous Thromboembolism Registry.
- Author
-
Spirk D, Willenberg T, Aujesky D, Husmann M, Hayoz D, Baldi T, Brugger A, Amann-Vesti B, Baumgartner I, and Kucher N
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Biomarkers, Embolectomy, Female, Humans, Male, Pulmonary Embolism etiology, Pulmonary Embolism therapy, Registries, Switzerland epidemiology, Thrombolytic Therapy, Treatment Outcome, Ventricular Dysfunction, Right complications, Echocardiography methods, Pulmonary Embolism diagnosis, Risk Assessment, Ventricular Dysfunction, Right diagnosis
- Abstract
Background: Cardiac biomarkers and echocardiography for assessing right ventricular function are recommended to risk stratify patients with acute non-massive pulmonary embolism (PE), but it remains unclear if these tests are performed systematically in daily practice., Design and Methods: Overall, 587 patients with acute non-massive PE from 18 hospitals were enrolled in the Swiss Venous Thromboembolism Registry (SWIVTER): 178 (30%) neither had a biomarker test nor an echocardiographic evaluation, 196 (34%) had a biomarker test only, 47 (8%) had an echocardiogram only and 166 (28%) had both tests., Results: Among the 409 (70%) patients with biomarkers or echocardiography, 210 (51%) had at least one positive test and 67 (16%) had positive biomarkers and right ventricular dysfunction. The ICU admission rates were 5.1% without vs. 5.6% with testing (P = 0.78), and thrombolysis or embolectomy were performed in 2.8% vs. 4.9%, respectively (P = 0.25). In multivariate analysis, syncope [odds ratio (OR): 3.49, 95% confidence interval (CI): 1.20-10.15; P = 0.022], tachycardia (OR: 2.31, 95% CI: 1.37-3.91; P = 0.002) and increasing age (OR: 1.02; 95% CI: 1.01-1.04; P < 0.001) were associated with testing of cardiac risk; outpatient status at the time of PE diagnosis (OR: 2.24, 95% CI: 1.49-3.36; P < 0.001), cancer (OR: 1.81, 95% CI: 1.17-2.79; P = 0.008) and provoked PE (OR: 1.58, 95% CI: 1.05-2.40; P = 0.029) were associated with its absence., Conclusion: Although elderly patients and those with clinically severe PE were more likely to receive a biomarker test or an echocardiogram, these tools were used in only two-thirds of the patients with acute non-massive PE and rarely in combination.
- Published
- 2012
- Full Text
- View/download PDF
18. Predictors of in-hospital mortality in elderly patients with acute venous thrombo-embolism: the SWIss Venous ThromboEmbolism Registry (SWIVTER).
- Author
-
Spirk D, Husmann M, Hayoz D, Baldi T, Frauchiger B, Engelberger R, Amann-Vesti B, Baumgartner I, and Kucher N
- Subjects
- Aged, Aged, 80 and over, Compression Bandages statistics & numerical data, Female, Fibrinolytic Agents therapeutic use, Humans, Male, Middle Aged, Prospective Studies, Pulmonary Embolism mortality, Pulmonary Embolism therapy, Recurrence, Registries, Reperfusion mortality, Reperfusion statistics & numerical data, Switzerland epidemiology, Thrombectomy mortality, Thrombectomy statistics & numerical data, Thrombolytic Therapy mortality, Thrombolytic Therapy statistics & numerical data, Treatment Outcome, Venous Thromboembolism therapy, Hospital Mortality, Venous Thromboembolism mortality
- Abstract
Aims: Although acute venous thrombo-embolism (VTE) often afflicts patients with advanced age, the predictors of in-hospital mortality for elderly VTE patients are unknown., Methods and Results: Among 1247 consecutive patients with acute VTE from the prospective SWIss Venous ThromboEmbolism Registry (SWIVTER), 644 (52%) were elderly (≥65 years of age). In comparison to younger patients, the elderly more often had pulmonary embolism (PE) (60 vs. 42%; P< 0.001), cancer (30 vs. 20%; P< 0.001), chronic lung disease (14 vs. 8%; P= 0.001), and congestive heart failure (12 vs. 2%; P< 0.001). Elderly VTE patients were more often hospitalized (75 vs. 52%; P< 0.001), and there was no difference in the use of thrombolysis, catheter intervention, or surgical embolectomy between the elderly and younger PE patients (5 vs. 6%; P= 0.54), despite a trend towards a higher rate of massive PE in the elderly (8 vs. 4%; P= 0.07). The overall in-hospital mortality rate was 6.6% in the elderly vs. 3.2% in the younger VTE patients (P= 0.033). Cancer was associated with in-hospital death both in the elderly [hazard ratio (HR) 4.91, 95% confidence interval (CI) 2.32-10.38; P< 0.001] and in the younger patients (HR 4.90, 95% CI 1.37-17.59; P= 0.015); massive PE was a predictor of in-hospital death in the elderly only (HR 3.77, 95% CI 1.63-8.74; P= 0.002)., Conclusion: Elderly patients had more serious VTE than younger patients, and massive PE was particularly life-threatening in the elderly.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.